Despite multimodal treatment, including surgery, radiotherapy, and chemotherapy, the prognosis for patients with WHO grade 4 astrocytomas or glioblastomas remains poor, regardless of IDH mutation status. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).